A New Model of Care for Familial Hypercholesterolaemia: What is the Role of Cardiology?
Gerald F Watts, David R Sullivan, Frank M van Bockxmeer, Nicola Poplawski, Ian Hamilton-Craig, Peter M Clifton, Richard C O'Brien, Warrick Bishop, Peter M George, Christopher Semsarian, Andrew Tonkin
HEART LUNG AND CIRCULATION | ELSEVIER SCIENCE INC | Published : 2012
Familial hypercholesterolaemia (FH) is a co-dominantly inherited disorder that causes marked elevation in plasma cholesterol and premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but most remain undiagnosed and undertreated. To bridge this gap in coronary prevention the FH Australasia Network has developed a model of care for FH. We present the executive summary, with a commentary contrasting the recommendations with other international guidelines and highlighting the role of the cardiologist.
Some members of the FH Australasia Network have received lecture honoraria, consultancy fees, and/or research funding from: Pfizer (G.F.W., D.S., I.H.C., P.M.C., R.O.B., W.B., A.T.), Astra Zeneca (G.F.W., D.S., I.H.C., P.M.C., R.O.B., W.B., A.T.), MSD (G.F.W., D.S., I.H.C., W.B., A.T.), Abbott (G.F.W., D.S., I.H.C., R.O.B., A.T.), Boehringer-Ingelheim (G.F.W., R.O.B., W.B., A.T.), Sanofi-Aventis (G.F.W., D.S., I.H.C., W.B.), Novartis (G.F.W., I.H.C., R.O.B., A.T.), GlaxoWellcome (G.F.W., I.H.C., R.O.B.), Bristol Myers Squibb (R.O.B., A.T.), Servier (I.H.C., P.M.C., R.O.B., W.B.), Roche (D.S.), Boston Scientific (C.S.).